Caitong International Asset Management Co. Ltd Invests $69,000 in Regeneron Pharmaceuticals, Inc. $REGN

Caitong International Asset Management Co. Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 131 shares of the biopharmaceutical company’s stock, valued at approximately $69,000.

Several other large investors have also recently made changes to their positions in the company. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals in the first quarter worth about $27,000. Colonial Trust Advisors purchased a new position in Regeneron Pharmaceuticals in the first quarter worth about $32,000. Finally, SouthState Corp boosted its position in shares of Regeneron Pharmaceuticals by 550.0% during the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 44 shares during the period. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on REGN. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price for the company. in a research report on Friday, August 1st. Canaccord Genuity Group restated a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a research report on Monday, August 4th. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $802.35.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $577.95 on Friday. The company has a market capitalization of $61.26 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.79 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $943.83. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $576.32 and a 200 day moving average of $562.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $11.56 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.